Literature DB >> 25040738

miRNA in hepatocellular carcinoma.

Asahiro Morishita1, Tsutomu Masaki1.   

Abstract

Hepatocellular carcinoma (HCC) is the third leading cause of cancer deaths worldwide. Despite improvements in HCC therapy, the prognosis for HCC patients remains poor due to a high incidence of recurrence. An improved understanding of the pathogenesis of HCC development would facilitate the development of more effective outcomes for the diagnosis and treatment of HCC at earlier stages. miRNA are small, endogenous, non-coding, ssRNA that are 21-30 nucleotides in length and modulate the expression of various target genes at the post-transcriptional and translational levels. Aberrant expression of miRNA is common in various human malignancies and modulates cancer-associated genomic regions or fragile sites. As for the relationship between miRNA and HCC, several studies have demonstrated that the aberrant expression of specific miRNA can be detected in HCC cells and tissues. However, little is known about the mechanisms of miRNA-related cell proliferation and development. In this review, we summarize the central and potential roles of miRNA in the pathogenesis of HCC and elucidate new possibilities that may be useful as diagnostic and prognostic markers, as well as novel therapeutic targets in HCC.
© 2014 The Authors. Hepatology Research published by Wiley Publishing Asia Pty Ltd on behalf of The Japan Society of Hepatology.

Entities:  

Keywords:  diagnostic and prognostic markers; hepatocellular carcinoma; miRNA; therapeutic target

Year:  2014        PMID: 25040738     DOI: 10.1111/hepr.12386

Source DB:  PubMed          Journal:  Hepatol Res        ISSN: 1386-6346            Impact factor:   4.288


  42 in total

Review 1.  Hepatocellular Carcinoma in Obesity, Type 2 Diabetes, and NAFLD.

Authors:  Helen L Reeves; Marco Y W Zaki; Christopher P Day
Journal:  Dig Dis Sci       Date:  2016-02-26       Impact factor: 3.199

2.  Bioinformatic analysis of microRNA networks following the activation of the constitutive androstane receptor (CAR) in mouse liver.

Authors:  Ruixin Hao; Shengzhong Su; Yinan Wan; Frank Shen; Ben Niu; Denise M Coslo; Istvan Albert; Xing Han; Curtis J Omiecinski
Journal:  Biochim Biophys Acta       Date:  2016-04-11

3.  miRNA-708 functions as a tumour suppressor in hepatocellular carcinoma by targeting SMAD3.

Authors:  Qi Li; Sheng Li; Yaolu Wu; Feng Gao
Journal:  Oncol Lett       Date:  2017-06-20       Impact factor: 2.967

4.  Berberine upregulates miR-22-3p to suppress hepatocellular carcinoma cell proliferation by targeting Sp1.

Authors:  Jie Chen; Fei-Xiang Wu; Hong-Lin Luo; Jun-Jie Liu; Tao Luo; Tao Bai; Le-Qun Li; Xiao-Hui Fan
Journal:  Am J Transl Res       Date:  2016-11-15       Impact factor: 4.060

5.  MiR-26b inhibits hepatocellular carcinoma cell proliferation, migration, and invasion by targeting EphA2.

Authors:  Hesheng Li; Qinglei Sun; Bing Han; Xingquan Yu; Baoguang Hu; Sanyuan Hu
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

6.  Targeted sequencing of cancer-associated genes in hepatocellular carcinoma using next-generation sequencing.

Authors:  Asahiro Morishita; Hisakazu Iwama; Shintaro Fujihara; Miwako Watanabe; Koji Fujita; Tomoko Tadokoro; Kyoko Ohura; Taiga Chiyo; Teppei Sakamoto; Shima Mimura; Takako Nomura; Joji Tani; Hirohito Yoneyama; Keiichi Okano; Yasuyuki Suzuki; Takashi Himoto; Tsutomu Masaki
Journal:  Oncol Lett       Date:  2017-11-02       Impact factor: 2.967

Review 7.  Diabetes mellitus and metformin in hepatocellular carcinoma.

Authors:  Koji Fujita; Hisakazu Iwama; Hisaaki Miyoshi; Joji Tani; Kyoko Oura; Tomoko Tadokoro; Teppei Sakamoto; Takako Nomura; Asahiro Morishita; Hirohito Yoneyama; Tsutomu Masaki
Journal:  World J Gastroenterol       Date:  2016-07-21       Impact factor: 5.742

8.  microRNA-762 promotes breast cancer cell proliferation and invasion by targeting IRF7 expression.

Authors:  Yongping Li; Ruixue Huang; Ling Wang; Junsheng Hao; Qiong Zhang; Rui Ling; Jun Yun
Journal:  Cell Prolif       Date:  2015-11-02       Impact factor: 6.831

9.  MicroRNA profiles during galectin-9-induced apoptosis of pancreatic cancer cells.

Authors:  Ryoichi Okura; Shintaro Fujihara; Hisakazu Iwama; Asahiro Morishita; Taiga Chiyo; Miwako Watanabe; Kayo Hirose; Kiyoyuki Kobayashi; Takayuki Fujimori; Kiyohito Kato; Hideki Kamada; Hideki Kobara; Hirohito Mori; Toshiro Niki; Mitsuomi Hirashima; Keiichi Okano; Yasuyuki Suzuki; Tsutomu Masaki
Journal:  Oncol Lett       Date:  2017-11-01       Impact factor: 2.967

10.  The Effect of Gemcitabine on Cell Cycle Arrest and microRNA Signatures in Pancreatic Cancer Cells.

Authors:  Daisuke Namima; Shintaro Fujihara; Hisakazu Iwama; Koji Fujita; Takanori Matsui; Mai Nakahara; Megumi Okamura; Masahiro Hirata; Toshiaki Kono; Naoki Fujita; Hiroki Yamana; Kiyohito Kato; Hideki Kamada; Asahiro Morishita; Hideki Kobara; Kunihiko Tsutsui; Tsutomu Masaki
Journal:  In Vivo       Date:  2020 Nov-Dec       Impact factor: 2.155

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.